Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Raymond W. Lam"'
Autor:
Amira Hmidan, Raymond W. Lam, Candice E Crocker, Philip G. Tibbo, Katherine J. Aitchison, Annie Trépanier, Kyle A. McKee, David Crockford, Jeffrey H. Meyer
Publikováno v:
Journal of Psychiatric Research. 140:267-281
The utility of cannabinoids and cannabinoid-based products (CBPs) as a pharmacological aid to treat psychiatric disorders in adulthood is still poorly understood despite a number of comprehensive general reviews discussing the topic. With a focus on
Autor:
Roumen Milev, Can-Bind Investigator Team, Wendy Lou, Sagar V. Parikh, Trisha Chakrabarty, Benicio N. Frey, Sidney H. Kennedy, Emma Morton, Daniel J. Müller, Erin E. Michalak, Shane McInerney, Peter Giacobbe, Raymond W. Lam, Susan Rotzinger, Venkat Bhat
Publikováno v:
CNS Drugs. 35:439-450
Non-response to first-line treatment for major depressive disorder (MDD) is common; for such individuals, quality of life (QoL) impairments can be severe. Identifying predictors of QoL changes may support the management of cases with persistent depre
Autor:
David J. Bond, Raymond W. Lam, Ivan J. Torres, Lakshmi N. Yatham, Leonardo Evangelista da Silveira
Publikováno v:
Psychological Medicine. 52:3783-3791
BackgroundWe previously reported that bipolar disorder (BD) patients with clinically significant weight gain (CSWG; ⩾7% of baseline weight) in the 12 months after their first manic episode experienced greater limbic brain volume loss than patients
Autor:
Sidney H. Kennedy, Wendy Lou, Sagar V. Parikh, Raymond W. Lam, Susan Rotzinger, Emma Morton, Peter Giacobbe, Daniel J. Müller, Erin E. Michalak, Roumen Milev, Can-Bind Investigator Team, Trisha Chakrabarty, Benicio N. Frey, Venkat Bhat
Publikováno v:
Pharmacopsychiatry. 54:225-231
Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals
Publikováno v:
Journal of Affective Disorders. 278:33-45
Background Condition-specific quality of life (QoL) instruments are more representative of the priorities of people with lived experience. As such, the development of the first and only bipolar disorder (BD) specific measurement instrument, the Quali
Autor:
Yousong Su, Jun Chen, Tao Yang, Raymond W. Lam, Weiping Xia, Hongmei Liu, Lu Yang, Jia Huang, Yiru Fang, Zuowei Wang, Na Zhu, Rubai Zhou, Jing Liu, Xiaorui Yang, Ruizhi Mao, Guoqing Zhao
Publikováno v:
Neuropsychiatric Disease and Treatment
Tao Yang,1,2 Raymond W Lam,2 Jia Huang,1 Yousong Su,1 Jing Liu,2 Xiaorui Yang,1 Lu Yang,1 Na Zhu,3 Guoqing Zhao,4 Ruizhi Mao,1 Rubai Zhou,1 Weiping Xia,5 Hongmei Liu,1 Zuowei Wang,6 Jun Chen,1 Yiru Fang1,7,8 1Clinical Research Center & Division of Mo
Autor:
Fidel Vila-Rodriguez, Raymond W. Lam, Daniel M. Blumberger, Jonathan Downar, Ivan J. Torres, Zafiris J. Daskalakis, Ruiyang Ge, Elizabeth Gregory
Publikováno v:
Journal of Affective Disorders. 274:593-601
Background Cognitive impairment is a well-recognized symptom of major depressive disorder; however, contributing factors are not fully characterized. The present study examined the neurocognitive profiles and predictors of cognitive impairment in pat
Publikováno v:
Journal of Affective Disorders. 270:30-35
Background Epidermal growth factor (EGF) belongs to a family of growth factors implicated in the etiology of psychiatric illnesses. We conducted this cross-sectional case-control study to determine whether (1) serum EGF levels differ between bipolar
Autor:
Kawai Leong, Amy Zwicker, Larry Ong, Sharon Willan, Alexander McGirr, Peter Chan, Raymond W. Lam
Publikováno v:
Can J Psychiatry
Objective: Despite effective psychological and pharmacological treatments, there is a large unmet burden of illness in post-traumatic stress disorder (PTSD). Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention and a puta
Autor:
Roumen Milev, Paul D. Metzak, Claudio N. Soares, Stephen R. Arnott, Jacqueline K. Harris, Nikita Nogovitsyn, Roberto Souza, Sagar V. Parikh, Mojdeh Zamyadi, Sidney H. Kennedy, Geoffrey B. Hall, Meghan Muller, Kate L. Harkness, Glenda MacQueen, Jonathan Downar, Stefanie Hassel, Stephen C. Strother, Benicio N. Frey, Susan Rotzinger, Raymond W. Lam, Zahinoor Ismail, Jean Addington, Andrew D. Davis
Publikováno v:
Neuropsychopharmacology
Finding a clinically useful neuroimaging biomarker that can predict treatment response in patients with major depressive disorder (MDD) is challenging, in part because of poor reproducibility and generalizability of findings across studies. Previous